Global Leading Market Research Publisher QYResearch announces the release of its latest report “Nucleic Acid-based Drugs – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. For pharmaceutical executives, biotechnology investors, and healthcare policymakers, the convergence of mRNA platform technology, lipid nanoparticle (LNP) delivery systems, and regulatory acceptance has ushered in a new era of therapeutic intervention. Traditional small molecules and protein therapeutics, while effective for many diseases, have fundamental limitations: they cannot address genetic root causes, face challenges in targeting intracellular pathways, and often fail against historically “undruggable” targets. Nucleic acid-based drugs—including antisense oligonucleotides (ASOs), siRNA, mRNA, and gene-editing vectors—overcome these limitations by intervening at the molecular level of disease, modulating gene expression with unprecedented specificity and designability. This report delivers a comprehensive strategic assessment of a market poised for sustained growth, quantifying the value proposition that is driving investment, clinical development, and commercialization across rare diseases, oncology, infectious diseases, and metabolic disorders as nucleic acid therapeutics transition from research-driven innovation to mainstream pharmaceutical platforms.
Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Nucleic Acid-based Drugs market, including market size, share, demand, industry development status, and forecasts for the next few years. The global market for Nucleic Acid-based Drugs was estimated to be worth US$ 14636 million in 2024 and is forecast to a readjusted size of US$ 21728 million by 2031 with a CAGR of 7.5% during the forecast period 2025-2031. Nucleic acid-based drugs are a new generation of biologics that use nucleic acids—including but not limited to antisense oligonucleotides (ASOs), siRNA, mRNA, aptamers, and gene-editing vectors—as active ingredients to modulate gene expression or directly replace/modify genetic information for therapeutic effect. Unlike conventional small molecules or protein therapeutics, nucleic acid drugs can intervene at the molecular root of disease with high target specificity and sequence designability, enabling access to historically “undruggable” targets. In recent years, advances in mRNA platforms, modified nucleotides, and delivery systems (such as lipid nanoparticles) have significantly accelerated clinical translation and industrial-scale manufacturing, moving the field rapidly from research-driven innovation toward commercialization and making it a core disruptive track in the pharmaceutical industry.
Opportunities in the nucleic acid drug sector stem from the convergence of technology and policy: platform advancements in mRNA, chemical nucleotide modification, and LNP delivery have shortened development timelines and expanded potential indications; regulatory acceptance and public-health prioritization have integrated nucleic acid products into national biopharmaceutical strategies, generating policy and procurement support. Meanwhile, sustained capital inflows and the commercial success of approved nucleic acid therapies are building an end-to-end ecosystem—from upstream materials and CMC to downstream distribution—creating immediate market expansion opportunities for companies with robust platforms and regulatory experience.
Despite promising prospects, commercialization faces material risks: delivery efficiency, tissue-specific targeting, and long-term safety require extensive clinical validation; upstream supply concentration and quality consistency of critical materials (modified nucleotides, lipid components, enzymes) challenge manufacturing resilience; regulatory heterogeneity and reimbursement/price uncertainties can slow adoption. Intensifying competition further means that without differentiated platforms and reliable manufacturing capability, new entrants will struggle to secure sustainable market positions.
Downstream demand is expanding from research and early clinical use to broader therapeutic and prophylactic applications. Clinically, rare diseases, genetic/metabolic disorders, oncology, and infectious disease vaccines drive strong demand for nucleic acid therapeutics; market-wise, healthcare institutions, specialty treatment centers, and commercial distribution networks are scaling to support chronic administration and cold-chain logistics; payer and buyer behavior is shifting from pilot or grant-driven uptake to value-driven procurement, with an increased focus on real-world effectiveness, cost-effectiveness, and accessibility—factors that will amplify demand for standardized, scalable nucleic acid formulations.
Key upstream inputs for nucleic acid drugs include synthesized and modified nucleotides, carrier materials (e.g., LNP components), high-purity enzymes and reagents, and GMP-grade consumables and equipment. As mRNA and siRNA products move to large-scale production, upstream requirements for quality, traceability, and batch consistency intensify, driving higher supplier concentration and the need for long-term supply agreements. Geographic dependencies and geopolitical risks are incentivizing companies to pursue localization and strategic inventory to ensure supply continuity and manufacturing resilience. The average gross profit margin of this product is 85%.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5181077/nucleic-acid-based-drugs
Market Trajectory: Sustained Growth Anchored in Platform Maturation and Regulatory Acceptance
The projected 7.5% CAGR reflects a market benefiting from the maturation of nucleic acid platforms and expanding therapeutic applications. According to recent data from industry analysts and regulatory agencies, the number of FDA-approved nucleic acid therapeutics has grown from fewer than 10 in 2015 to over 20 in 2024, with the pipeline containing over 500 candidates across early and late-stage development. The commercial success of mRNA COVID-19 vaccines—generating over US$ 50 billion in revenue—validated the platform and accelerated investment across the sector.
Several factors are driving market expansion. The commercial success of siRNA therapeutics—including Alnylam’s ONPATTRO for hATTR amyloidosis—has demonstrated the viability of RNA interference for chronic diseases. Advances in LNP delivery have enabled tissue-specific targeting, expanding the addressable indications for nucleic acid drugs. Additionally, the integration of nucleic acid platforms into national biopharmaceutical strategies has generated policy and procurement support that reduces commercial risk.
Technology Segmentation: ASO, siRNA, mRNA, and Beyond
The market’s segmentation by modality—Antisense Oligonucleotides (ASO) , siRNA, mRNA, and Other—reveals distinct technology platforms with different mechanisms of action and clinical applications.
ASO and siRNA represent the established segment for rare genetic diseases, with drugs targeting neuromuscular disorders, hATTR amyloidosis, and other conditions where gene silencing is therapeutic. A case study from a neurology center illustrates the impact: patients with spinal muscular atrophy (SMA) treated with the ASO nusinersen demonstrated significant motor function improvement, with clinical trial data showing 51% of infantile-onset patients achieving motor milestones never seen in untreated populations.
mRNA represents the fastest-growing segment, driven by vaccine applications and expanding therapeutic programs for oncology, rare diseases, and protein replacement. The success of mRNA vaccines has catalyzed investment in manufacturing capacity and delivery technology that benefits the broader nucleic acid field.
Exclusive Industry Insight: The Manufacturing Capacity Imperative
The defining challenge—and opportunity—in the nucleic acid-based drugs market is the scaling of GMP manufacturing capacity. The industry average gross profit margin of 85% reflects the high value of these therapeutics, but also underscores the critical importance of manufacturing reliability.
For strategic decision-makers, the nucleic acid-based drugs market presents a compelling opportunity characterized by sustained growth, platform diversification, and the foundational role of these therapeutics in addressing previously untreatable diseases. The projected expansion from US$ 14.64 billion to US$ 21.73 billion by 2031 reflects a market where delivery technology, manufacturing capability, and clinical validation will define competitive success.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
